We have shown that LV‐mediated gene therapy employing autologous, peripheral blood‐mobilised CD34+ HSPCs with non‐myeloablative conditioning is a safe treatment modality in a Phase 1 cohort of five male Fabry disease patients. The gene discussed is CD34; the disease is Fabry disease.